ROXILOX
Clinical safety rating
cautionComprehensive clinical and safety monograph for ROXILOX (ROXILOX).
Roxilox is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
| Metabolism | Hepatic via CYP2C9 and CYP3A4; undergoes glucuronidation. |
| Excretion | Renal (70-80% unchanged), biliary/fecal (15-20%), remainder metabolized |
| Half-life | Terminal elimination half-life 4.5 hours; prolonged to 18-24 hours in severe renal impairment (CrCl <30 mL/min) |
| Protein binding | ~95% bound to serum albumin |
| Volume of Distribution | 0.3-0.5 L/kg, consistent with distribution in extracellular fluid and moderate tissue penetration |
| Bioavailability | Oral: 60-70% due to moderate first-pass metabolism; IV: 100% |
| Onset of Action | Oral: 30-60 minutes; IV: immediate |
| Duration of Action | Oral: 6-8 hours; IV: 4-6 hours; prolonged in renal impairment |
| Molecular Weight | 331.34 |
10 mg orally once daily, with or without food.
| Dosage form | CAPSULE |
| Renal impairment | eGFR 30-89 mL/min: no adjustment; eGFR 15-29 mL/min: 5 mg once daily; eGFR <15 mL/min or dialysis: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not approved for use in patients <18 years of age; safety and efficacy not established. |
| Geriatric use | No initial dose adjustment required; monitor renal function and titrate cautiously due to age-related decline in GFR. |
| 1st trimester | Roxiloxacin is contraindicated in first trimester due to risk of arthropathy and fetal cartilage damage observed in animal studies. No adequate human studies available. |
| 2nd trimester | Avoid use in second trimester unless absolutely necessary; potential risk of fetal bone development interference. |
| 3rd trimester | Avoid use in third trimester; associated with neonatal arthralgia and possible cartilage erosion. |
Clinical note
Comprehensive clinical and safety monograph for ROXILOX (ROXILOX).
| Placental transfer | Roxiloxacin crosses the placenta with high efficiency; fetal serum concentrations reach 50-80% of maternal levels. |
| Breastfeeding | Roxiloxacin is excreted into human breast milk. Due to potential for serious adverse reactions in nursing infants, including joint and cartilage damage, advise against breastfeeding during therapy and for 5-7 days after last dose. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | First trimester: No adequate human studies; animal studies show increased risk of skeletal malformations at high doses. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to potential uteroplacental vasoconstriction. Avoid unless maternal benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure and renal function. Assess fetal growth and amniotic fluid volume via ultrasound every 4-6 weeks. Consider non-stress test or biophysical profile in third trimester if uteroplacental insufficiency suspected. |
| Fertility Effects | No adverse effects on fertility observed in animal studies. Human data insufficient; theoretical risk of hormonal disruption at high doses. |
■ FDA Black Box Warning
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use and in patients with cardiovascular risk factors. Roxilox is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
| Serious Effects |
Hypersensitivity to roxiloxacin or any fluoroquinoloneHistory of tendon disorders related to fluoroquinolone usePatients under 18 years of age (except for specific indications)PregnancyBreastfeeding
| Precautions | Use lowest effective dose for shortest duration; caution in patients with history of gastrointestinal bleeding, renal impairment, fluid retention, hypertension, asthma, and in elderly; monitor renal function, hepatic function, and blood pressure. |
| Food/Dietary | Avoid grapefruit and grapefruit juice, as they inhibit CYP3A4 and may increase ROXILOX levels. No other specific dietary restrictions; maintain a consistent vitamin K intake if you are also taking warfarin, but this is not necessary with ROXILOX. |
| Clinical Pearls | ROXILOX is a novel oral anticoagulant (NOAC) that inhibits factor Xa. It does not require routine coagulation monitoring. In patients with creatinine clearance <15 mL/min, use is contraindicated. Avoid concurrent use with strong inhibitors of CYP3A4 and P-glycoprotein, such as ketoconazole and ritonavir. Epidural or spinal hematomas may occur in patients receiving neuraxial anesthesia or undergoing spinal puncture. |
| Patient Advice | Take this medication exactly as prescribed. Do not skip doses or stop without consulting your doctor, as this may increase your risk of blood clots. · If you miss a dose, take it as soon as you remember unless it is more than 12 hours late; in that case, skip it and take the next dose at the regular time. · Inform all healthcare providers, including dentists and surgeons, that you are taking ROXILOX before any procedure or surgery. · Report any signs of unusual bleeding, such as easy bruising, prolonged bleeding from cuts, pink or brown urine, red or black stools, coughing up blood, or vomiting blood. · Avoid concurrent use of other blood thinners (e.g., warfarin, aspirin) unless specifically directed by your doctor. · Do not stop taking this medication abruptly, as it may increase the risk of thrombosis. · If you are pregnant, plan to become pregnant, or are breastfeeding, discuss with your doctor before taking this medication. |
Loading safety data…